Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC).
Aged
CTLA-4 Antigen
/ metabolism
Carcinoma, Squamous Cell
/ immunology
Female
Follow-Up Studies
Head and Neck Neoplasms
/ immunology
Humans
Immune Checkpoint Proteins
/ metabolism
Immunotherapy
/ methods
Longitudinal Studies
Lymphocytes, Tumor-Infiltrating
/ metabolism
Male
Middle Aged
Programmed Cell Death 1 Receptor
/ metabolism
Prospective Studies
T-Lymphocyte Subsets
/ metabolism
cancer immunotherapy
curative treatment
head and neck squamous cell carcinoma
immune checkpoint
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 04 2021
15 04 2021
Historique:
received:
18
07
2020
revised:
01
11
2020
accepted:
13
11
2020
pubmed:
19
12
2020
medline:
3
8
2021
entrez:
18
12
2020
Statut:
ppublish
Résumé
Programmed-death-1 (PD1) antibodies are approved for recurrent and metastatic head and neck squamous cell carcinoma. Multiple drugs targeting costimulatory and coinhibitory immune checkpoint molecules (ICM) have been discovered. However, it remains unknown how these ICM are affected by curative conventional therapy on different immune cell subsets during the course of treatment. In the prospective noninterventional clinical study titled "Immune Response Evaluation to Curative conventional Therapy" (NCT03053661), 22 patients were prospectively enrolled. Blood samples were drawn at defined time points throughout curative conventional treatment and follow-up. Immune cells (IC) from the different time points were assessed by multicolor flow cytometry. The following ICM were measured by flow cytometry: PD1, CTLA4, BTLA, CD137, CD27, GITR, OX40, LAG3 and TIM3. Dynamics of ICM expression were assessed using nonparametric paired samples tests. Significant changes were noted for PD1, BTLA and CD27 on multiple IC types during or after radiotherapy. Nonsignificant trends for increased expression of OX40 and GITR from baseline until the end of RT were observed on CD4 T cells and CD4
Substances chimiques
CTLA-4 Antigen
0
CTLA4 protein, human
0
Immune Checkpoint Proteins
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Banques de données
ClinicalTrials.gov
['NCT03053661']
Types de publication
Clinical Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2023-2035Informations de copyright
© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492.
National Comprehensive Cancer Network (NCCN) Guidelines: Head and Neck Cancers. Version 1.2020. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915-1928.
Cohen EEW, Soulieres D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393:156-167.
Ferris RL, Blumenschein GJ, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. New Engl J Med. 2016;375:1856-1867.
Doescher J, Busch CJ, Wollenberg B, et al. Immunotherapy for head and neck cancer: highlights of the 2019 ASCO annual meeting. HNO. 2019;67:905-911.
Doescher J, Laban S, Schuler PJ, Brunner C, Hoffmann TK. Immunotherapy for head and neck cancers: an update and future perspectives. Immunotherapy. 2019;11:561-564.
Manukian G, Bar-Ad V, Lu B, Argiris A, Johnson JM. Combining radiation and immune checkpoint blockade in the treatment of head and neck squamous cell carcinoma. Front Oncol. 2019;9:122.
Mytilineos D, Ezić J, von Witzleben A, et al. Peripheral cytokine levels differ by HPV status and change treatment-dependently in patients with head and neck squamous cell carcinoma. Int J Mol Sci. 2020;21(17):5990. https://doi.org/10.3390/ijms21175990.
Jacobs MV, de Roda Husman AM, van den Brule AJ, Snijders PJ, Meijer CJ, Walboomers JM. Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol. 1995;33:901-905.
Borsellino G, Kleinewietfeld M, Di Mitri D, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110:1225-1232.
Micallef L, Rodgers P. eulerAPE: drawing area-proportional 3-Venn diagrams using ellipses. PLoS One. 2014;9:e101717.
Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol. 2005;23:23-68.
Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18:155.
Bogdándi EN, Candéias S, Garcia LC, et al. Radiotherapy-induced changes in the systemic immune and inflammation parameters of head and neck cancer patients. Cancers. 2019;11(9):1324. https://doi.org/10.3390/cancers11091324.
Kimmeyer J, Kurzweg T, Hoffmann TK, et al. Oncologic treatment landscape for head and neck squamous cell carcinoma: treatment infrastructure in German-speaking countries. HNO. 2016;64:494-500.
Kurzweg T, Kimmeyer J, Knecht R, et al. Curative treatment of head and neck squamous cell carcinoma: organ preservation strategies in clinical routine in German-speaking countries. HNO. 2016;64:501-507.
Li D, Chen R, Wang YW, Fornace AJ Jr, Li HH. Prior irradiation results in elevated programmed cell death protein 1 (PD-1) in T cells. Int J Radiat Biol. 2018;94:488-494.
Hecht M, Gostian A, Eckstein M, et al. Single cycle induction treatment with cisplatin/docetaxel plus durvalumab/tremelimumab in stage III-IVB head and neck squamous cell cancer (CHECKRAD-CD8 trial). Ann Oncol. 2019;30(suppl_5):v449-v474.
Machiels J-PH, Licitra L, Rischin D, et al. KEYNOTE-412: pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). J Clin Oncol. 2017;35:TPS6090-TPS.
Bonomo P, Desideri I, Loi M, et al. Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: a phase I/II study (DUCRO). Clin Transl Radiat Oncol. 2018;9:42-47.
Yu Y, Lee NY. JAVELIN head and neck 100: a phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer. Future Oncol. 2019;15:687-694.
Uppaluri R, Lee NY, Westra W, et al. KEYNOTE-689: phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma. J Clin Oncol. 2019;37:TPS6090-TPS.
Cillo AR, Kurten CHL, Tabib T, et al. Immune landscape of viral- and carcinogen-driven head and neck cancer. Immunity. 2020;52:183-99 e9.
Long M, Beckwith K, Do P, et al. Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest. 2017;127:3052-3064.
Chen YL, Lin HW, Chien CL, et al. BTLA blockade enhances cancer therapy by inhibiting IL-6/IL-10-induced CD19(high) B lymphocytes. J Immunother Cancer. 2019;7:313.
Radvanyi LG, Bernatchez C, Zhang M, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012;18:6758-6770.
Turaj AH, Hussain K, Cox KL, et al. Antibody tumor targeting is enhanced by CD27 agonists through myeloid recruitment. Cancer Cell. 2017;32:777-91.e6.
Trivedi S, Srivastava RM, Concha-Benavente F, et al. Anti-EGFR targeted monoclonal antibody isotype influences antitumor cellular immunity in head and neck cancer patients. Clin Cancer Res. 2016;22:5229-5237.
Braig F, Kriegs M, Voigtlaender M, et al. Cetuximab resistance in head and neck cancer is mediated by EGFR-K521 polymorphism. Cancer Res. 2017;77:1188-1199.
Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020;20:173-185.
Mohme M, Schliffke S, Maire CL, et al. Immunophenotyping of newly diagnosed and recurrent glioblastoma defines distinct immune exhaustion profiles in peripheral and tumor-infiltrating lymphocytes. Clin Cancer Res. 2018;24:4187-4200.
Williams P, Basu S, Garcia-Manero G, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125:1470-1481.
Takenaka MC, Robson S, Quintana FJ. Regulation of the T cell response by CD39. Trends Immunol. 2016;37:427-439.
Gu J, Ni X, Pan X, et al. Human CD39(hi) regulatory T cells present stronger stability and function under inflammatory conditions. Cell Mol Immunol. 2017;14:521-528.
Fang F, Yu M, Cavanagh MM, et al. Expression of CD39 on activated T cells impairs their survival in older individuals. Cell Rep. 2016;14:1218-1231.
Dwyer KM, Hanidziar D, Putheti P, et al. Expression of CD39 by human peripheral blood CD4+ CD25+ T cells denotes a regulatory memory phenotype. Am J Transplant. 2010;10:2410-2420.
Duhen T, Duhen R, Montler R, et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. 2018;9:2724.
Kortekaas KE, Santegoets SJ, Sturm G, et al. CD39 identifies the CD4(+) tumor-specific T-cell population in human cancer. Cancer Immunol Res. 2020;8:1311-1321.
Allan SE, Crome SQ, Crellin NK, et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol. 2007;19:345-354.
Santegoets SJ, Dijkgraaf EM, Battaglia A, et al. Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol Immunother. 2015;64:1271-1286.
Wild CA, Bergmann C, Fritz G, et al. HMGB1 conveys immunosuppressive characteristics on regulatory and conventional T cells. Int Immunol. 2012;24:485-494.
Wild CA, Brandau S, Lotfi R, et al. HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer. Oral Oncol. 2012;48:409-416.
Giraldo NA, Becht E, Vano Y, et al. Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma. Clin Cancer Res. 2017;23:4416-4428.
Kovacsovics-Bankowski M, Chisholm L, Vercellini J, et al. Detailed characterization of tumor infiltrating lymphocytes in two distinct human solid malignancies show phenotypic similarities. J Immunother Cancer. 2014;2:38.
Foulds GA, Vadakekolathu J, Abdel-Fatah TMA, et al. Immune-phenotyping and transcriptomic profiling of peripheral blood mononuclear cells from patients with breast cancer: identification of a 3 gene signature which predicts relapse of triple negative breast cancer. Front Immunol. 2018;9:2028.